Top Medical News
2 days ago
Impaired estimated glomerular filtration rate (eGFR) independently predicts tumour recurrence in nonmuscle-invasive bladder cancer (NMIBC) after bacillus Calmette-Gue’rin (BCG) immunotherapy, a new study shows.
Audrey Abella, 2 days ago
The minimally invasive laparoscopic liver resection (LLR) appears to be a safe and feasible alternative to open liver resection (OLR) for patients with liver metastasis from colorectal cancer (CRC), according to a study.
2 days ago
The development of resistance to cytarabine is associated with increased sensitivity to glucocorticoids in acute myeloid leukaemia (AML) patients with wild-type Fms-Related Tyrosine Kinase 3 (FLT3) mutation, a study has shown.
Tristan Manalac, 3 days ago
Women with higher age at breast cancer diagnosis and Indian women are at a higher risk of cardiovascular disease (CVD) mortality after diagnosis, a new prospective cohort study shows. However, risk of CVD mortality within 10 years after diagnosis remains low in Southeast Asia.
7 days ago
In ovarian cancer patients, social support was negatively associated with symptoms of post-traumatic stress disorder (PTSD) and could explain variations in the symptoms, a new study shows.
8 days ago
Effective physician communication with chronic liver disease patients is important with respect to the risks of developing liver cancer and the significance of regular screening, particularly among nonwhites and those with lower education, suggests a recent study.
8 days ago
Serum chemerin levels have a weak but significant association with quality of life (QoL) of survivors of colorectal cancer (CRC), a new study shows.
Special Reports
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Jairia Dela Cruz, 06 Dec 2016
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
Conference Reports
Christina Lau, 10 May 2017

The use of granulocyte colony stimulating-factor (G-CSF) is safe in patients with limited-stage small-cell lung cancer (SCLC) treated with chemoradiotherapy, according to a post hoc analysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) 2017.

Christina Lau, 09 May 2017

Ensartinib, a small-molecule ALK tyrosine kinase inhibitor (TKI), has demonstrated intracranial response in patients with ALK-positive non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastases.

Christina Lau, 09 May 2017

Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.

Christina Lau, 09 May 2017

Patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of immune-related adverse events (irAEs) after receiving seasonal influenza vaccination, a small study presented at the European Lung Cancer Conference (ELCC) 2017 has shown.

Pearl Toh, 09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

28 Feb 2017
Slideshow: Highlights from the 7th Association of South-East Asian Pain Societies (ASEAPS) Congress 2017
Tristan Manalac, 25 Feb 2017
Compared with viral hepatocellular carcinomas and those of other aetiologies, cryptogenic hepatocellular carcinomas tend to manifest at later stages and are associated with worse survival, according to a study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017).
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!